Orforglipron and Heart Events in People With Heart Artery Disease or Chronic Kidney Disease
Tests orforglipron against placebo for heart problems in adults with artery or kidney disease.
Plain-language title generated from the registry record
Registry title: A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Key facts
- Where
- Actopan, Ciudad Madero, Cuernavaca, Culiacán, Durango, Guadalajara, Hermosillo, León, Mérida, Mexicali, México, Mexico City, Monterrey, Tijuana, Veracruz, and Villahermosa, MexicoSee the 35 sites
- Phase
- Phase 3
Where in Mexico
- Centro de Atencion al Diabetico ActopanActopan, MexicoNot yet recruiting
- Centro de Estudios de Investigacion Metabolicos y Cardiovasculares, S.C.Ciudad Madero, MexicoTaking people
- Instituto de Diabetes, Obesidad y NutricionCuernavaca, MexicoTaking people
- Centro Para El Desarrollo de La Medicina Y de Asistencia Medica Especializada S.C.Culiacán, MexicoTaking people
- Instituto de Investigaciones Aplicadas a la Neurociencia A.C.Durango, MexicoTaking people
- Lahoja. Asociacion Para La Investigacion Y La FarmacovigilanciaDurango, MexicoNot yet recruiting
- Diseno y Planeacion en Investigacion MedicaGuadalajara, MexicoTaking people
- Instituto Jalisciense de Investigacion en Diabetes y ObesidadGuadalajara, MexicoNot yet recruiting
- Unidad de Investigación Clínica y Atención Médica HEPA S.C.Guadalajara, MexicoTaking people
- Hermosillo Heart Team - Sinacor HermosilloHermosillo, MexicoNot yet recruiting
- Investigación Médica Sonora, S.C.Hermosillo, MexicoNot yet recruiting
- Instituto Cardiovascular de León S.C.León, MexicoNot yet recruiting
- Centro de Desarrollo BiomedicoMérida, MexicoNot yet recruiting
- Medical Care and Research Sa de CvMérida, MexicoNot yet recruiting
- Centro de Investigacion en Artritis y Osteoporosis SCMexicali, MexicoNot yet recruiting
- Centro de investigación y control metabólicoMéxico, MexicoTaking people
- Instituto Nacional de Cardiologia Ignacio ChavezMéxico, MexicoTaking people
- Centro de Investigacion Clinica ChapultepecMexico City, MexicoTaking people
- Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades CardiovascularesMexico City, MexicoTaking people
- Centro Médico Nacional Siglo XXIMexico City, MexicoNot yet recruiting
- Gastrobariátrica Santa FeMexico City, MexicoNot yet recruiting
- Grupo Medico Camino ScMexico City, MexicoTaking people
- Hospital de Jésus, I.A.P.Mexico City, MexicoNot yet recruiting
- Hospital Juarez de MexicoMexico City, MexicoNot yet recruiting
- Instituto Nacional de Cardiologia Ignacio ChavezMexico City, MexicoNot yet recruiting
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránMexico City, MexicoNot yet recruiting
- RM Pharma Specialists - Unidad Especializada en DatosMexico City, MexicoTaking people
- Cardiolink Clin TrialsMonterrey, MexicoTaking people
- CEINV SaludMonterrey, MexicoNot yet recruiting
- Clínica García Flores SCMonterrey, MexicoTaking people
- Servicios de Oncología Medica Integral - Monterrey - José BenitezMonterrey, MexicoTaking people
- UBAM Unidad Biomedica Avanzada MonterreyMonterrey, MexicoNot yet recruiting
- Centro de Investigacion Cardiovascular y MetabólicaTijuana, MexicoNo longer taking part
- FAICIC S. de R.L. de C.V.Veracruz, MexicoTaking people
- Integradora Multidisciplinaria Del Grijalva - Sinacor VillahermosaVillahermosa, MexicoNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07241390EU 2025-523123-22-00
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.Read full original descriptionShow less
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Inclusion: Have established ASCVD and/or CKD.
Exclusion: Have had a major heart condition within 60 days prior to screening; Have type 1 diabetes; Have New York Heart Association Functional Classification Class IV heart failure.